Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
Results showed a significant reduction in transfusion burden compared to placebo

Safety profile generally consistent with previously reported data

Regulatory submissions planned in the United States and Europe in the first half of 2019